Can France Stay in the Game?
This article was originally published in Start Up
The French government's efforts to encourage biotechnology have been modest and somewhat piecemeal. Yet two years ago, France's industry was nevertheless ranked second in Europe. Since then, the explosion of biotech companies in Germany, along with steady growth in other European markets, make the need for a coherent French strategy more urgent. France needs to take some bolder, more generous measures--particularly to reduce companies' tax burden and attract talent from overseas--without which it risks restricting itself to a small group of companies, many of whom will have to move elsewhere to grow substantially.
You may also be interested in...
Recent concerns over the cardiovascular risk profile of Cox-2 inhibitors strengthen the case for pain compound AZD 3582, a new formulation of naproxen in Phase II trials at AstraZeneca. For the compound's originator, NicOx, forthcoming trial results will be critical in validating the firm's founding concept: grafting a nitric oxide molecule onto existing generic drugs.
Entrepreneur Philippe Pouletty, president of France Biotech, spells out to In Vivo Europe what's holding France's industry back, and what newly elected President Jacques Chirac needs to do about it.
The creation of Roche spin-off BioXell may signal a change in Italy's hitherto unfriendly biotech environment. Yet much remains to be done.